Oxidative Stress on Muscle Dysfunction in Hemodialysis Patient (POPEYE)

January 29, 2021 updated by: University Hospital, Montpellier

Impact of the Oxidative Stress on the Skeletal Muscle Dysfunction in Hemodialysis Patient

In hemodialysis patient (HD) a reduction of the skeletal muscle mass and strength has previously been reported. This muscle impairment constitutes an independent prognosis factor in HD patients. Oxidative stress and inflammation have been linked to the muscle impairment. The mitochondria is a classical producer and target of reactive oxygen species (ROS), and may thus constitute a central actor of the skeletal muscle impairment in HD patients. Therefore, the aim of the present study is to investigate the role of the muscle mitochondrial density on the muscle impairment in HD patients, in comparing the muscle mitochondrial density and oxidative stress in HD patients vs. healthy matched controls.

In order to assess the effect of the oxidative stress and inflammation on the muscle impairment in HD patients, muscle function assessements will be performed after renal transplantation (which lowers the oxidative stress and inflammation levels) in the HD patient group.

No therapeutic intervention will be tested in the present study.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Montpellier, France, 34295
        • Montpellier University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 40-80 years old
  • less than 150min by week of moderate to vigorous physical activity
  • Chronic renal failure (glomerular filtration rate less than 15mL by min) requiring hemodialysis
  • Patient placed on the kidney transplant waiting list of MontpellierCHU
  • No indication against temporary kidney transplant
  • Review cardiovascular older than two years
  • Patient not under guardianship or trusteeship
  • Clinically stable state Absence or recent infection within 3 months prior to inclusion Absence of progressive neoplasia No recent acute decompensation of chronic disease (thrust of heart failure, respiratory decompensated cirrhosis).

Absence of recent stroke

  • musculoskeletal and neurological states of the lower limbs which allow the realization of the proposed functional tests.
  • Patient has given written informed consent
  • Absence of congenital or genetic degenerative muscle disease

Exclusion Criteria:

  • Terminal chronic renal failure without replacement therapy
  • Local anesthesic hypersensibility
  • Corticosteroid treatment upper than 3 month
  • COPD
  • Oral anticoagulants
  • Previous renal transplantation
  • Subject not affiliated with a social security scheme, beneficiary or not such a plan
  • Major subject protected by law or unable to consent under Article L 1121-8 of the Public Health Code
  • Vulnerable person under Article L.1121-6 of the Public Health Code

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Healthy volunteers
Other: No intervention
Experimental: HD patient
Procedure: renal transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Muscle mitochondrial density assessed on a quadriceps biopsy by immunochemistry
Time Frame: 2 years
2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Maximum voluntary contraction of the quadriceps (in Newton.meter)
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2015

Primary Completion (Actual)

March 1, 2018

Study Completion (Actual)

March 1, 2018

Study Registration Dates

First Submitted

May 26, 2016

First Submitted That Met QC Criteria

June 3, 2016

First Posted (Estimate)

June 8, 2016

Study Record Updates

Last Update Posted (Actual)

February 3, 2021

Last Update Submitted That Met QC Criteria

January 29, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9459-2

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Renal Failure Requiring Hemodialysis

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe